This week's Fierce Life Sciences is brought to you by Allucent.

Article: Harnessing Antibody-Drug Conjugates (ADCs) in Oncology: Pathways to Clinical Success

ADCs are reshaping cancer treatment. Once experimental, antibody-drug conjugates (ADCs) are approved for breast, lung, and blood cancers. By combining targeted antibodies with potent payloads, ADCs offer a powerful, precise approach to therapy. Advances in linker and payload technology are boosting their efficacy and safety, paving the way for broader impact.

Want more engaging content? Click here to see more!